Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$13.1MCash on Hand
30.2mo Cash Runway
Follow OPTH by emailGet an email when OPTH reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about OPTH, unsubscribe in one click. Privacy
📣 What OPTH Says Is Next
in 2027 · “The Proposed Phase 3 Trial is expected to begin in 2027.”
Company press release, Oct 20, 2026 · SEC filing
next year · ““With both trials expected to begin enrolling patients next year, this timely appointment strengthens our ability to generate the data to bring these treatments to the underserved patient populations who need them most." Dr. Blough is a medical researcher with more than 20 years of experience directing research programs spanning bench science, pre-clinical studies, and clinical trials.”
Company press release, Sep 22, 2026 · SEC filing
first half of 2027 · “The trial is planned to be initiated in the first half of 2027, with dosing expected to be complete by the end of 2027.”
Company press release, Sep 10, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Oct 26, 2026 ·
Leadership Optimi Health formed Optimi Australia Pty Ltd, a wholly owned subsidiary to handle sales, distribution and prescriber relationships in Australia. It appointed Adrian Jones, formerly of Bristol Myers Squibb, as Director of Australian Operations. Form 6-K · SEC filing · Press release
Oct 20, 2026 ·
Optimi Health completed a new MDMA production batch at its Princeton, B.C. GMP facility. The batch will supply a proposed Canadian Phase 3 PTSD trial expected to begin in 2027, a commercial export to Australia planned before end of 2026, and an Israeli trial with MAPS. Form 6-K · SEC filing · Press release
Oct 7, 2026 ·
Optimi Health will present a corporate overview at the ThinkEquity Conference in New York City on October 15, 2026, at 4:00 p.m. Eastern, and will hold one-on-one investor meetings. Form 6-K · SEC filing · Press release
Sep 29, 2026 ·
Leadership Appointed Melanie Pump, CFO of Qu Data Centres, to its Board of Directors. Corporate Secretary Leah Hodges resigned, and CEO Dane Stevens was appointed to fill the role. Form 6-K · SEC filing · Press release
Sep 23, 2026 ·
Optimi completed one cGMP batch of 5mg psilocybin capsules at its Princeton, B.C. facility under its Health Canada Drug Establishment Licence. The batch will supply the Health Canada-approved Phase 2 MDD trial of up to 200 participants, with patient dosing expected to finish by end of 2027, and Australian clinics. Form 6-K · SEC filing · Press release
Sep 22, 2026 ·
Leadership Appoints Dr. Michael Blough, Ph.D., as Chief Clinical Development Officer, a newly created role overseeing clinical strategy, including a planned Phase 2 psilocybin trial in major depressive disorder and a Phase 3 MDMA trial in PTSD, with both trials expected to begin enrolling next year. Form 6-K · SEC filing · Press release
Sep 16, 2026 ·
Announces plans for a Health Canada-authorized Phase 3 trial of synthetic MDMA-assisted therapy for PTSD, expected to begin in 2027, enrolling up to 100 participants in Canada. The primary endpoint is change in the CAPS-5 score. None of its MDMA products are yet authorized by Health Canada. Form 6-K · SEC filing · Press release
Sep 10, 2026 ·
Clinical trial Optimi Health plans a Health Canada-authorized Phase 2 trial of single-dose natural psilocybin for major depressive disorder, enrolling up to 200 participants, with dosing expected to finish by end of 2027. The trial is planned to start in the first half of 2027 and will be funded from current cash on hand. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
OPTH holds $13.1M in cash and short-term investments and burns about $1.3M/quarter from operations,
an estimated runway of 30.2 months at that rate (BioRadar estimate, not company guidance).
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OPTH and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.